文献速递类风湿关节炎

ABP 501 与阿达木单抗治疗中重度类风湿关节炎的疗效与安全性:随机双盲 III 期等效性研究

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
PubMed 文献 · Ann Rheum Dis · 2017-06-05

这项随机双盲 III 期等效性研究纳入 526 例甲氨蝶呤应答不足的中重度活动性类风湿关节炎患者,按 1:1 随机接受 ABP 501 或阿达木单抗 40 mg 每两周一次,治疗 26 周。第 24 周 ACR20 风险比(90%CI)为 1.039(0.954,1.133),落在预设等效区间 0.738–1.355 内,证实 ABP 501 与阿达木单抗在疗效、安全性和免疫原性方面相似。

要点

  • 第 24 周 ACR20 风险比 90%CI 为 1.039(0.954,1.133),落在等效区间 0.738–1.355 内。
  • ABP 501 组与阿达木单抗组 ACR20 分别为 74.6% 与 72.4%,DAS28-CRP、ACR50、ACR70 变化相似。
  • 抗药结合抗体阳性率分别为 38.3% 与 38.2%,不良事件与实验室异常无临床有意义差异。

核心结论

  • ABP 501 在中重度类风湿关节炎患者中的临床疗效、安全性和免疫原性与阿达木单抗相似。

研究设计与样本

  • 随机、双盲、活性对照、26 周等效性 III 期研究,纳入甲氨蝶呤治疗后仍为中重度活动性 RA 的患者 526 例,按 1:1 随机接受 ABP 501 或阿达木单抗 40 mg 每两周一次。

主要发现

  • 第 24 周 ACR20 应答率 ABP 501 组为 74.6%、阿达木单抗组为 72.4%。
  • 第 24 周两组 ACR20 风险比(90%CI)为 1.039(0.954,1.133),确认等效性假设。
  • DAS28-CRP、ACR50 和 ACR70 自基线变化相似,不良事件与实验室异常无临床有意义差异。
  • 抗药结合抗体阳性率 ABP 501 组为 38.3%、阿达木单抗组为 38.2%。

关键数值与推荐

  • 主要终点为第 24 周组间 ACR20 风险比,若其 90%CI 落在 0.738 至 1.355 之间则确认等效。
  • 共 526 例患者随机(ABP 501 组 264 例,阿达木单抗组 262 例),494 例完成研究。

临床怎么用

  • 该研究支持 ABP 501 作为阿达木单抗生物类似药用于中重度类风湿关节炎的临床等效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: ABP 501 is a Food and Drug Administration-approved biosimilar to adalimumab; structural, functional and pharmacokinetic evaluations have shown that the two are highly similar. We report results from a phase III study comparing efficacy, safety and immunogenicity between ABP 501 and adalimumab. METHODS: In this randomised, double-blind, active comparator-controlled, 26-week equivalence study, patients with moderate to severe active rheumatoid arthritis (RA) despite methotrexate were randomised (1:1) to ABP 501 or adalimumab (40 mg) every 2 weeks. Primary endpoint was risk ratio (RR) of ACR20 between groups at week 24. Primary hypothesis that the treatments were equivalent would be confirmed if the 90% CI for RR of ACR20 at week 24 fell between 0.738 and 1.355, demonstrating that ABP 501 is similar to adalimumab. Secondary endpoints included Disease Activity Score 28-joint count-C reactive protein (DAS28-CRP). Safety was assessed via adverse events (AEs) and laboratory evaluations. Antidrug antibodies were assessed to determine immunogenicity. RESULTS: A total of 526 patients were randomised (n=264, ABP 501; n=262 adalimumab) and 494 completed the study. ACR20 response at week 24 was 74.6% (ABP 501) and 72.4% (adalimumab). At week 24, the RR of ACR20 (90% CI) between groups was 1.039 (0.954, 1.133), confirming the primary hypothesis. Changes from baseline in DAS28-CRP, ACR50 and ACR70 were similar. There were no clinically meaningful differences in AEs and laboratory abnormalities. A total of 38.3% (ABP 501) and 38.2% (adalimumab) of patients tested positive for binding antidrug antibodies. CONCLUSIONS: Results from this study demonstrate that ABP 501 is similar to adalimumab in clinical efficacy, safety and immunogenicity in patients with moderate to severe RA. TRIAL REGISTRATION NUMBER: NCT01970475; Results.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017. PMID: 28584187. doi:10.1136/annrheumdis-2016-210459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。